Predicting endocrine therapy responsiveness in breast cancer

ONCOLOGY

Volumn 23, Issue 2, 2009, Pages 133-142

  Ma, Cynthia X ^a   Sanchez, Cesar G ^a   Ellis, Matthew J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GOSERELIN; KI 67 ANTIGEN; LETROZOLE; LEUPRORELIN; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN P53; RALOXIFENE; TAMOXIFEN; TOREMIFENE; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; BREAST SURGERY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; ENDOMETRIUM CANCER; FOLLOW UP; FRAGILITY FRACTURE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LIFE EXPECTANCY; MUSCULOSKELETAL DISEASE; OVERALL SURVIVAL; PATIENT SELECTION; PREDICTION; PREOPERATIVE EVALUATION; PROGNOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; THROMBOSIS; TREATMENT OUTCOME; VASOMOTOR DISORDER;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 63249095994     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Beatson G: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 2:104, 1896.
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005.
3. Anderson H, Bulun S, Smith I, et al: Predictors of response to aromatase inhibitors. J Steroid Biochem Mol Biol 106:49-54, 2007.
4. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569-1583, 2005.
5. Perez EA: Appraising adjuvant aromatase inhibitor therapy. Oncologist 11:1058-1069, 2006.
6. Osborne CK, Yochmowitz MG, Knight WA, 3rd, et al: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46:2884-2888, 1980.
7. Bezwoda WR, Esser JD, Dansey R, et al: The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer 68:867-872, 1991.
8. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998.
9. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005.
10. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999.
11. Baehner FL, Habel LA, Quesenberry CP, et al: Quantitative RT-PCR analysis of ER and PR by Oncotype DX indicates distinct and different associations with prognosis and prediction of tamoxifen benefit (abstract 45). Breast Cancer Res Treat 100(suppl 1):S20, 2006.
12. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001.
13. Ellis MJ, Ma C: Letrozole in the neoadjuvant setting: The P024 trial. Breast Cancer Res Treat 105(suppl 1):33-43, 2007.
14. Smith IE, Dowsett M, Ebbs SR, et al: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108-5116, 2005.
15. Allred DC: Problems and solutions in he evaluation of hormone receptors in breast cancer. J Clin Oncol 26:2433-2435, 2008.
16. Bamberger AM, Milde-Langosch K, Schulte HM, et al: Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: Correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm Res 54:32-37, 2000.
17. Arpino G, Weiss H, Lee AV, et al: Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254-1261, 2005.
18. Creighton CJ, Kent Osborne C, van de Vijver MJ, et al: Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat Apr 19, 2008 (epub ahead of print).
19. Elledge RM, Green S, Pugh R, et al: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study. Int J Cancer; 89:11 1- 117, 2000.
20. Ravdin PM, Green S, Dorr TM, et al: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol 10:1284-1291, 1992.
21. Dowsett M, Houghton J, Iden C, et al: Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17:818-826, 2006.
22. Dowsett M, Cuzick J, Wale C, et al: Retrospective analysis of time to recurrence in the atac trial according to hormone receptor status: An hypothesis-generating study. J Clin Oncol 23:7512-7517, 2005.
23. Dowsett M, Allred C, Knox J, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059-1065, 2008.
24. Mauriac L, Keshaviah A, Debled M, et al: Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 18:859-867, 2007.
25. Lal P, Tan LK, Chen B: Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 123:541-546, 2005.
26. Kaptain S, Tan LK, Chen B: Her-2/neu and breast cancer. Diagn Mol Pathol 10:139-152, 2001.
27. Pietras RJ, Arboleda J, Reese DM, et al: Her-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446, 1995.
28. Liu Y, el-Ashry D, Chen D, et al: MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34:97-117, 1995.
29. Benz CC, Scott GK, Sarup JC, et al: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95, 1992.
30. Oh AS, Lorant LA, Holloway JN, et al: Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 15:1344-1359, 2001.
31. Wright C, Nicholson S, Angus B, et al: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992.
32. Ellis MJ, Tao Y, Young O, et al: Estrogen-independent cell proliferation Occurs in the majority of estrogen receptor positive (ER+)/HER2 gene-amplified primary breast cancers: Evidence from a combined analysis of two independent neoadjuvant letrozole studies (abstract 9538). J Clin Oncol 23(16S):846s, 2005.
33. De Placido S, De Laurentiis M, Carlomagno C, et al: Twenty-year results of the naples gun randomized trial: Predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 9:1039-1046, 2003.
34. Rasmussen BB, Regan MM, Lykkesfeldt AE, et al: Adjuvant letrozole versus tamoxifen according to centrally-assessed erbB2 status for postmenopausal women with endocrine-responsive early breast cancer: Supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 9:23-28, 2008.
35. Viale G, Regan MM, Malorano E, et al: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846-3852, 2007.
36. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005.
37. Gerdes J, Schwab U, Lemke H, et al: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation, Int J Cancer 31:13-20, 1983.
38. Gerdes J, Lemke H, Baisch H, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984.
39. Spyratos F, Ferrero-Pous M, Trassard M, et al: Correlation between MIB-1 and other proliferation markers: Clinical implications of the MIB-1 cutoff value. Cancer 94:2151-2159, 2002.
40. van Diest PJ, van der Wall E, Baak JPA: Prognostic value of proliferation in invasive breast cancer: A review. J Clin Pathol 57:675-681, 2004.
41. Urruticoechea A, Smith IE, Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23:7212-7220, 2005.
42. de Azambuja E, Cardoso F, de Castro G Jr, et al: Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. Br J Cancer 96:1504-1513, 2007.
43. Goldhirsch A, Wood WC, Gelber RD, et al: Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357-3365, 2003.
44. Chang J, Ormerod M, Powles TJ, et al: Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 89:2145-2152, 2000.
45. Archer CD, Parton M, Smith IE, et al: Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 89:1035-1041, 2003.
46. Viale G, Regan MM, Mastropasqua MG, et al: Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100:207-212, 2008.
47. Thurlimann B, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005.
48. Coates AS, Keshaviah A, Thurlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for post-menopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007.
49. Viale G, Giobbie-Hurder A, Regan MM, et al: Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from Breast International Group trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26:5569-5575, 2008.
50. Viale G, Giobbie-Hurder A: Value of centrally-assessed Ki-67 labeling index as a marker of prognosis and predictor of response to adjuvant endocrine therapy in the BIG 1-98 trial of postmenopansal women with estrogen receptor-positive breast cancer (abstract 64). Presented at the 30th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas; Dec 13-16, 2007.
51. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004.
52. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000.
53. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98:10869-10874, 2001.
54. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 100:8418-8423, 2003.
55. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002.
56. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast Cancer. J Clin Oncol 19:980-991, 2001.
57. Bogaerts J, Cardoso F, Buyse M, et al: Gene signature evaluation as a prognostic tool: Challenges in the design of the mindact trial. Nat Clin Pract Oncol 3:540-551, 2006.
58. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006.
59. Paik S, Shak S, Tang G, et al: Expression of the 21 genes in the recurrence score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20 (abstract 24). Presented at the 27th Annual San Antonio Breast Cancer Symposium, Dec 8-11, 2004.
60. Parker JS, Mullins M, Cheang MC, et al: A supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol.
61. Cheang M, Chia SK, Voduc D: Ki67 and HER2 define luminal B breast cancers with poor prognosis. J Natl Cancer Inst. In press.
62. Hugh J, Hanson J, Cheang M, et al: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. In press.
63. Macaskill EJ, Renshaw L, Dixon JM: Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer. Oncologist 11:1081-1088, 2006.
64. Eiermann W, Paepke S, Appfelstaedt J, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527-1532, 2001.
65. Clarke RB, Laidlaw IJ, Jones LJ, et al: Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 67:606-611, 1993.
66. Dowsett M, Smith IE, Ebbs SR, et al: Short-term changes in Ki-67 during neoadjurant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11:951s-958s, 2005.
67. Ellis MJ, Coop A, Singh B, et al: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63:6523-6531, 2003.
68. Dowsett M, Smith IE, Ebbs SR, et al: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167-170, 2007.
69. Ellis MJ, Tat Y, Luo J, et al: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380-1388, 2008.
70. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002.
71. Dowsett M, Smith IE, Ebbs SR, et al: Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11:951 s-958s, 2005.
72. Ellis MJ, Tat Y, Luo J, et al: A poor prognosis ER and HER2-negative, nonbasal, breast cancer subtype identified through post-neoadjuvant endocrine therapy tumor profiling (abstract 502). J Clin Oncol 26(15S):7s, 2008.
73. Morrow DA, Antman EM, Charlesworth A, et al: TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102:2031-2037, 2000.